Resilient Lifescience is a technology company.
Resilient Lifescience has raised $125K across 2 funding rounds.
Resilient Lifescience has raised $125K in total across 2 funding rounds.
Resilient Lifescience has raised $125K in total across 2 funding rounds.
Resilient Lifescience's investors include Evergreen Climate Innovations, Innovation Works.
Resilient Lifescience is a Pittsburgh-based technology company developing a wearable medical device aimed at preventing opioid overdose deaths. Their product uses non-invasive sensing technology to detect opioid-induced respiratory depression (OIRD) and automatically delivers naloxone, a life-saving opioid antagonist, even when no one else is present. This device serves people living with opioid addiction and their loved ones by providing an automated emergency response to overdoses, addressing a critical gap in overdose intervention. The company has shown early growth momentum with a team experienced in medical device development, entrepreneurship, and addiction medicine, and is currently engaging a beta community to refine its technology[1][2][3][4][5].
Founded in Pittsburgh, Resilient Lifescience emerged from a commitment to leverage medical device technology to combat the opioid crisis. The company’s leadership, including CEO and CTO Charlie Proctor, brings decades of expertise in medical devices and addiction medicine. The idea originated from the urgent need to provide an immediate, automated response to opioid overdoses, which often occur when no one is around to administer naloxone. Early traction includes developing a prototype wearable device that detects OIRD and automatically administers naloxone, with ongoing beta testing involving affected individuals to shape the product’s development[1][2][3].
Resilient Lifescience is positioned at the intersection of wearable health technology and addiction medicine, riding the trend of digital health solutions addressing public health crises. The opioid epidemic remains a major challenge globally, and the timing is critical as wearable tech becomes more sophisticated and accepted. Market forces such as increasing opioid-related deaths, demand for automated emergency interventions, and advances in sensor technology favor the company’s innovation. By automating overdose detection and reversal, Resilient Lifescience could significantly influence how medical devices contribute to harm reduction and emergency response in addiction care[3][4].
Looking ahead, Resilient Lifescience aims to advance its wearable device through clinical validation and regulatory approval, scaling its impact on opioid overdose prevention. Trends shaping its journey include growing adoption of wearable health monitors, increased public and governmental focus on opioid crisis solutions, and technological improvements in drug delivery systems. As the company matures, its influence may extend beyond opioid addiction to other emergency medical interventions, potentially setting new standards for automated, wearable emergency care devices. This innovation ties back to its core mission of saving lives through technology when seconds count[2][3].
Resilient Lifescience has raised $125K across 2 funding rounds. Most recently, it raised $50K Seed in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $50K Seed | Evergreen Climate Innovations, Innovation Works | |
| May 1, 2022 | $75K Seed |